Loading...
•
Sep 30, 2021
Curis Q3 2021 Earnings Report
Curis reported financial results for the third quarter ended September 30, 2021 and provided business updates.
Key Takeaways
Curis reported a net loss of $11.1 million, or $0.12 per share, for the third quarter of 2021, compared to a net loss of $6.0 million, or $0.11 per share, for the same period in 2020. Revenues for the third quarter of 2021 were $3.0 million, compared to $2.7 million for the same period in 2020. The company's cash, cash equivalents and investments totaled $149.8 million as of September 30, 2021.
Advanced clinical trials of CA-4948, a small molecule IRAK4 inhibitor, across nine distinct patient populations.
Initiated dosing in the combination stage of the Phase 1/2 study of CA-4948 plus azacitidine and CA-4948 plus venetoclax.
New preclinical data highlighting the potential of CA-4948 in additional hematologic malignancies was presented.
Enrollment remains on track in the ongoing Phase 1 dose escalation study of CI-8993.
Revenue by Segment
Forward Guidance
Curis plans to provide a clinical data update in January from ongoing clinical studies, including safety data from the Phase 1 study of CI-8993 and the latest safety and efficacy data from the CA-4948 study in AML/MDS patients with spliceosome or FLT3 mutations.
Positive Outlook
- Provide a clinical data update on ongoing studies in January.
- Report initial safety data from the Phase 1 monotherapy study of CI-8993.
- Share the latest safety and efficacy data from the Phase 1/2 monotherapy study of CA-4948 in AML/MDS patients.
- Provide additional data from the ongoing Phase 1/2 monotherapy study of CA-4948 in patients with R/R AML/MDS at a medical meeting in the first half of the year.
- Report initial data at a medical meeting from the ongoing Phase 1/2 combination study of CA-4948 plus ibrutinib in patients with B cell cancers in the first half of the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...